|
"su w c"的相關文件
顯示項目 186-195 / 419 (共42頁)
<< < 14 15 16 17 18 19 20 21 22 23 > >>
每頁顯示[10|25|50]項目
| 臺大學術典藏 |
2020-07-01T08:53:22Z |
Postural Control and Interceptive Skills in Children with Autism Spectrum Disorder
|
Chen L.-C.;Su W.-C.;Ho T.-L.;Lu L.;Tsai W.-C.;Chiu Y.-N.;Suh-Fang Jeng; Chen L.-C.; Su W.-C.; Ho T.-L.; Lu L.; Tsai W.-C.; Chiu Y.-N.; SUH-FANG JENG |
| 臺大學術典藏 |
2020-06-30T08:10:04Z |
R331W missense mutation of oncogene YAP1 is a germline risk allele for lung adenocarcinoma with medical actionability
|
KANG-YI SU; Hsu Y.-C.; Chang C.-S.; Li Y.-C.; Yang S.-Y.; Hsu P.-Y.; Ho H.; Chang Y.-H.; Chen C.-Y.; Yang H.-I.; Hsu C.-P.; Yang T.-Y.; Chen K.-C.; Hsu K.-H.; Tseng J.-S.; Hsia J.-Y.; Chuang C.-Y.; Yuan S.; Lee M.-H.; Liu C.-H.; Wu G.-I.; Hsiung C.A.; Chen Y.-M.; Wang C.-L.; Huang M.-S.; Yu C.-J.; Chen K.-Y.; Tsai Y.-H.; Su W.-C.; Chen H.-W.; Chen J.J.W.; Chen C.-J.; Chang G.-C.; Yang P.-C.; Li K.-C.; Chen H.-Y.;Yu S.-L.;Ho B.-C.;Kang-Yi Su;Hsu Y.-C.;Chang C.-S.;Li Y.-C.;Yang S.-Y.;Hsu P.-Y.;Ho H.;Chang Y.-H.;Chen C.-Y.;Yang H.-I.;Hsu C.-P.;Yang T.-Y.;Chen K.-C.;Hsu K.-H.;Tseng J.-S.;Hsia J.-Y.;Chuang C.-Y.;Yuan S.;Lee M.-H.;Liu C.-H.;Wu G.-I.;Hsiung C.A.;Chen Y.-M.;Wang C.-L.;Huang M.-S.;Yu C.-J.;Chen K.-Y.;Tsai Y.-H.;Su W.-C.;Chen H.-W.;Chen J.J.W.;Chen C.-J.;Chang G.-C.;Yang P.-C.;Li K.-C.; Ho B.-C.; Yu S.-L.; Chen H.-Y. |
| 臺大學術典藏 |
2020-06-18T06:09:56Z |
Chloroboron subphthalocyanine/C60 planar heterojunction organic solar cell with N,N-dicarbazolyl-3,5-benzene blocking layer
|
Chen, L.-C.;Lee, J.-H.;Chen, C.-T.;Han, H.-C.;Chiu, T.-L.;Su, W.-C.;Lee, C.-C.;Liu, S.-W.;Wei, M.-K.;Bardeen, C.J.;Cheng, Y.-C.;Nichols, V.M.;Lin, C.-F.; Lin, C.-F.; Nichols, V.M.; Cheng, Y.-C.; Bardeen, C.J.; Wei, M.-K.; Liu, S.-W.; Lee, C.-C.; Su, W.-C.; Chiu, T.-L.; Han, H.-C.; Chen, L.-C.; Chen, C.-T.; Lee, J.-H. |
| 臺大學術典藏 |
2020-06-18T06:09:53Z |
A new anodic buffer layer material for non-mixed planar heterojunction chloroboron subphthalocyanine organic photovoltaic achieving 96% internal quantum efficiency
|
Chen, L.-C.;Lee, J.-H.;Chen, C.-T.;Han, H.-C.;Chiu, T.-L.;Huang, J.-C.;Su, W.-C.;Kubota, M.;Sakurai, T.;Lee, C.-C.;Liu, S.-W.;Lin, C.-F.; Lin, C.-F.; Liu, S.-W.; Lee, C.-C.; Sakurai, T.; Kubota, M.; Su, W.-C.; Huang, J.-C.; Chiu, T.-L.; Han, H.-C.; Chen, L.-C.; Chen, C.-T.; Lee, J.-H. |
| 臺大學術典藏 |
2020-06-17T03:01:38Z |
R331W missense mutation of oncogene YAP1 is a germline risk allele for lung adenocarcinoma with medical actionability
|
Chen H.-Y.;Sung-Liang Yu;Ho B.-C.;Su K.-Y.;Hsu Y.-C.;Chang C.-S.;Li Y.-C.;Yang S.-Y.;Hsu P.-Y.;Ho H.;Chang Y.-H.;Chen C.-Y.;Yang H.-I.;Hsu C.-P.;Yang T.-Y.;Chen K.-C.;Hsu K.-H.;Tseng J.-S.;Hsia J.-Y.;Chuang C.-Y.;Yuan S.;Lee M.-H.;Liu C.-H.;Wu G.-I.;Hsiung C.A.;Chen Y.-M.;Wang C.-L.;Huang M.-S.;Yu C.-J.;Chen K.-Y.;Tsai Y.-H.;Su W.-C.;Chen H.-W.;Chen J.J.W.;Chen C.-J.;Chang G.-C.;Yang P.-C.;Li K.-C.; Chen H.-Y.; SUNG-LIANG YU; Ho B.-C.; Su K.-Y.; Hsu Y.-C.; Chang C.-S.; Li Y.-C.; Yang S.-Y.; Hsu P.-Y.; Ho H.; Chang Y.-H.; Chen C.-Y.; Yang H.-I.; Hsu C.-P.; Yang T.-Y.; Chen K.-C.; Hsu K.-H.; Tseng J.-S.; Hsia J.-Y.; Chuang C.-Y.; Yuan S.; Lee M.-H.; Liu C.-H.; Wu G.-I.; Hsiung C.A.; Chen Y.-M.; Wang C.-L.; Huang M.-S.; Yu C.-J.; Chen K.-Y.; Tsai Y.-H.; Su W.-C.; Chen H.-W.; Chen J.J.W.; Chen C.-J.; Chang G.-C.; Yang P.-C.; Li K.-C. |
| 臺大學術典藏 |
2020-06-11T06:17:54Z |
High-performance organic photovoltaic device using a new amorphous molecular material of bis(4-(N-(l-naphthyl)phenylamino) phenyl)fumaronitrile
|
Liu, S.-W.;Lee, C.-C.;Su, W.-C.;Lin, C.-F.;Huang, J.-C.;Chen, C.-T.;Lee, J.-H.; Liu, S.-W.; Lee, C.-C.; Su, W.-C.; Lin, C.-F.; Huang, J.-C.; Chen, C.-T.; Lee, J.-H.; JIUN-HAW LEE |
| 臺大學術典藏 |
2020-05-26T09:27:22Z |
High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy
|
Kao W.-Y.;Lin Z.-Z;Yu C.-T;Kuo H.-P;Chang W.-C;Yu C.-J;Chung C.-Y;Ho M.-L;Wang J.-L;Huang M.-S;Chen C.-H;Chen H.-C;Hsia T.-C;Tsao C.-J;Su W.-C;Lai R.-S;Chu N.-M;Hsieh R.-K;Lin M.-C;Chang G.-C;Chen Y.-M;Chih-Hsin Yang;Perng R.-P; Perng R.-P; CHIH-HSIN YANG; Chen Y.-M; Chang G.-C; Lin M.-C; Hsieh R.-K; Chu N.-M; Lai R.-S; Su W.-C; Tsao C.-J; Hsia T.-C; Chen H.-C; Chen C.-H; Huang M.-S; Wang J.-L; Ho M.-L; Chung C.-Y; Yu C.-J; Chang W.-C; Kuo H.-P; Yu C.-T; Lin Z.-Z; Kao W.-Y. |
| 臺大學術典藏 |
2020-05-26T09:27:07Z |
Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial
|
Miller V.A.;Yang P.-C;Lorence R.M;Cong X.J;Shahidi M;Dudek A.Z;Sequist L.V;Ho C.-L;Chang G.-C;Yu C.-J;Ou S.H.I;Tsai C.-M;Hsia T.-C;Su W.-C;Shih J.-Y;Chih-Hsin Yang; CHIH-HSIN YANG; Shih J.-Y; Su W.-C; Hsia T.-C; Tsai C.-M; Ou S.H.I; Yu C.-J; Chang G.-C; Ho C.-L; Sequist L.V; Dudek A.Z; Shahidi M; Cong X.J; Lorence R.M; Yang P.-C; Miller V.A. |
| 臺大學術典藏 |
2020-05-26T09:27:07Z |
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase 2b/3 randomised trial
|
Chih-Hsin Yang;Lorence R.M;Cong X.J;Shahidi M;Chao T.-Y;Tan E.-H;Crino L;Heo D.S;Sun Y;Wang M;Su W.-C;Zhou C;Kim S.-W;Park K;Chen Y.-M;Cadranel J;Hirsh V;Miller V.A; Miller V.A; Hirsh V; Cadranel J; Chen Y.-M; Park K; Kim S.-W; Zhou C; Su W.-C; Wang M; Sun Y; Heo D.S; Crino L; Tan E.-H; Chao T.-Y; Shahidi M; Cong X.J; Lorence R.M; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:27:01Z |
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations
|
Sequist L.V;Chih-Hsin Yang;Yamamoto N;O'Byrne K;Hirsh V;Mok T;Geater S.L;Orlov S;Tsai C.-M;Boyer M;Su W.-C;Bennouna J;Kato T;Gorbunova V;Lee K.H;Shah R;Massey D;Zazulina V;Shahidi M;Schuler M.; Sequist L.V; CHIH-HSIN YANG; Yamamoto N; O'Byrne K; Hirsh V; Mok T; Geater S.L; Orlov S; Tsai C.-M; Boyer M; Su W.-C; Bennouna J; Kato T; Gorbunova V; Lee K.H; Shah R; Massey D; Zazulina V; Shahidi M; Schuler M. |
顯示項目 186-195 / 419 (共42頁)
<< < 14 15 16 17 18 19 20 21 22 23 > >>
每頁顯示[10|25|50]項目
|
